Drug Ther Bull. 1996 Oct;34(10):78-80.
Each year about 26,000 people in Britain develop colorectal cancer. Roughly half of these patients die from locally advanced or metastatic disease. Systemic chemotherapy, usually with regimens including fluorouracil, can prolong survival in patients with advanced or recurrent disease and may improve their quality of life. [symbol: see text] Raltitrexed (Tomudex-Zeneca), a new class of cytotoxic drug introduced last year, is claimed to simplify treatment and be as effective as one established fluorouracil regimen while causing less toxicity. We review raltitrexed and assess its place in the treatment of patients in whom colorectal cancer is advanced.
在英国，每年约有26000人罹患结直肠癌。其中约一半患者死于局部晚期或转移性疾病。全身化疗通常采用含氟尿嘧啶的方案，可延长晚期或复发性疾病患者的生存期，并可能改善其生活质量。[符号：见正文]雷替曲塞（商品名：拓优得，由捷利康公司生产）是去年推出的一类新型细胞毒性药物，据称该药物可简化治疗，疗效与一种成熟的氟尿嘧啶方案相当，但毒性更低。我们对雷替曲塞进行综述，并评估其在晚期结直肠癌患者治疗中的地位。
